胰岛素市场机会、成长要素、产业趋势分析及2026-2035年预测

预计到 2025 年，全球胰岛素市值将达到 292 亿美元，并有望以 3.4% 的复合年增长率成长，到 2035 年达到 414 亿美元。

全球胰岛素市场的整体成长主要受糖尿病（尤其是第2型糖尿病）盛行率上升的驱动。 2型糖尿病与久坐的生活方式、肥胖率上升以及人口老化密切相关。此外，不良的饮食习惯、高热量摄取、遗传倾向以及生活方式相关的压力等因素也导致了该疾病发生率的增加。胰岛素是一种天然激素，在调节血糖值方面发挥重要作用。它是由胰臟中的特殊细胞产生，并在血糖值升高时分泌。这使得葡萄糖能够被身体细胞吸收，并被用作能量或储存起来以备后用。如果身体无法产生足够的胰岛素或对胰岛素的反应不佳，血糖值就会升高，进而导致糖尿病。胰岛素市场包含多种产品类型，包括速效、短效、中效、长效胰岛素、预混合料製剂和生物相似药。全球市场高度集中，少数几家跨国製药公司占据了大部分的生产和技术研发份额。

预计到2025年，胰岛素类似物市场规模将达223亿美元。与传统人类胰岛素製剂相比，胰岛素类比产品凭藉其更佳的临床疗效、更高的安全性以及更便捷的治疗方式，保持着强劲的市场地位。这些治疗方法因能降低血糖值剧烈波动的风险并提高患者的整体治疗顺从性而广受认可。胰岛素类似物还具有更大的给药柔软性，使患者能够更方便地管理治疗。给药便捷和患者满意度的提高促进了其广泛应用。此外，某些长效胰岛素类似物製剂能带来更稳定的治疗效果并减少治疗相关併发症，进一步推动了市场需求。

到2025年，长效胰岛素市占率将达到45.3%。长效胰岛素製剂旨在缓慢释放胰岛素，从而在较长时间内维持血液中基准水平的稳定。这种缓慢释放是透过一种特殊的製剂机制实现的，该机制允许药物在皮下注射后缓慢吸收。有些长效胰岛素製剂能够长期维持疗效，进而减少患者所需的注射次数。这种持续作用有助于维持血糖稳定，同时降低血糖值快速波动的风险。因此，长效胰岛素疗法因其能够提高治疗依从性并提供更可预测的血糖管理而被广泛采用。

预计到2025年，北美胰岛素市占率将达到40.1%。北美在胰岛素产业的主导地位主要得益于糖尿病的高发生率以及全人群对胰岛素治疗的强劲需求。许多患者依赖胰岛素来控制病情，确保了整个医疗保健系统对胰岛素的稳定使用。先进的医疗基础设施、强大的诊断能力以及最新胰岛素製剂和给药技术的广泛应用，进一步巩固了北美的市场主导地位。

目录

第一章：调查方法和范围

第二章执行摘要

第三章业界考察

• 生态系分析
• 影响产业的因素
  • 促进因素
    • 糖尿病盛行率上升
    • 胰岛素输送系统的进展
    • 政府措施和政策
  • 产业潜在风险与挑战
    • 胰岛素高成本
    • 替代疗法的可近性
  • 市场机会
    • 关注儿童糖尿病
    • 生物相似胰岛素产品的扩张
• 成长潜力分析
• 监理情势（基于初步调查）
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
  • 亚太地区
• 价格分析（基于初步调查）
• 管道分析（基于初步调查）
• 糖尿病现状
  • 全球各地区糖尿病患者人数
  • 2050年全球糖尿病患者人数最多的国家（2024年）
  • 2024年全球糖尿病盛行率最高的国家
  • 2024年全球糖尿病患者人数估计及至2050年的预测
  • 预计2050年全球糖尿病患者人数最多的国家
  • 糖尿病医疗保健支出排名前十的国家
  • 区域细分：全球未确诊糖尿病患者人数
  • 各地区未确诊糖尿病患者的百分比
• 人工智慧和生成式人工智慧对市场的影响
• 波特五力分析
• PESTEL 分析

第四章 竞争情势

• 介绍
• 企业市占率分析
  • 北美洲
  • 欧洲
  • 亚太地区
• 企业矩阵分析
• 主要市场公司的竞争分析
• 竞争定位矩阵
• 主要进展
  • 併购
  • 伙伴关係与合作
  • 新产品发布
  • 业务拓展计划

第五章 市场估计与预测：依类型划分，2022-2035年

• 人类胰岛素
• 胰岛素类似物

第六章 市场估算与预测：依产品划分，2022-2035年

• 速效胰岛素
• 长效胰岛素
• 配方胰岛素
• 生物相似药
• 其他产品

第七章 市场估计与预测：依应用领域划分，2022-2035年

• 1型糖尿病
• 2型糖尿病
• 妊娠糖尿病

第八章 市场估算与预测：依通路划分，2022-2035年

• 医院药房
• 零售药房
• 网路药房

第九章 市场估计与预测：依地区划分，2022-2035年

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国

第十章：公司简介

• Adocia
• Biocon
• Boehringer Ingelheim International
• Eli Lilly and Company
• Gan & Lee Pharmaceuticals
• Gland Pharma
• Julphar
• MannKind Corporation
• Novo Nordisk
• Pfizer
• Sanofi
• Shanghai Fosun Pharmaceutical
• Tonghua Dongbao Pharmaceutical
• United Laboratories International
• Wockhardt

The Global Insulin Market was valued at USD 29.2 billion in 2025 and is estimated to grow at a CAGR of 3.4% to reach USD 41.4 billion by 2035.

Growth across the insulin market is driven by the rising prevalence of diabetes worldwide, particularly type 2 diabetes, which is increasingly associated with sedentary lifestyles, increasing obesity levels, and an aging population. Additional factors such as poor dietary habits, higher caloric intake, genetic susceptibility, and lifestyle-related stress are also contributing to the growing incidence of the disease. Insulin is a naturally occurring hormone responsible for regulating glucose levels in the bloodstream. It is produced by specialized cells in the pancreas and released when blood sugar levels increase, enabling glucose to move into body cells where it is utilized for energy or stored for later use. When the body either fails to produce adequate insulin or cannot effectively respond to it, blood glucose levels rise, leading to diabetes. The insulin market includes multiple product categories such as rapid-acting, short-acting, intermediate-acting, long-acting, premixed insulin formulations, and biosimilar insulin products. The global market remains highly consolidated, with a limited number of multinational pharmaceutical companies accounting for a significant portion of production and technological development.

The insulin analog segment reached USD 22.3 billion in 2025. Insulin analog products maintain a strong position in the market because they offer improved clinical outcomes, enhanced safety profiles, and greater treatment convenience compared with conventional human insulin formulations. These therapies are widely recognized for reducing the risk of severe blood sugar fluctuations and improving overall treatment adherence. Insulin analogs also provide greater dosing flexibility, allowing patients to manage therapy more conveniently. Their ease of administration and improved patient satisfaction contribute to their widespread adoption. In addition, certain long-acting analog formulations are associated with more stable treatment outcomes and reduced treatment-related complications, which further supports their demand.

The long-acting insulin segment held a 45.3% share in 2025. Long-acting insulin formulations are designed to release insulin gradually, maintaining a consistent baseline level in the bloodstream over an extended duration. Their slow activity is achieved through formulation mechanisms that allow gradual absorption after subcutaneous injection. Some long-acting insulin products can remain effective for extended periods, which reduces the frequency of injections required for patients. This extended action helps maintain stable glucose control while lowering the risk of sudden fluctuations in blood sugar levels. As a result, long-acting insulin therapies are widely adopted because they improve treatment adherence and provide more predictable blood glucose management.

North America Insulin Market generated 40.1% share in 2025. The region's leadership within the insulin industry is strongly supported by the significant prevalence of diabetes and the high demand for insulin therapy across the population. Many patients rely on insulin to manage their condition, resulting in strong and consistent product utilization across healthcare systems. The presence of advanced medical infrastructure, strong diagnostic capabilities, and broad access to modern insulin formulations and delivery technologies further reinforces North America's leading market position.

Key companies operating in the Global Insulin Market include Novo Nordisk, Sanofi, Eli Lilly and Company, Pfizer, Biocon, Boehringer Ingelheim International, Adocia, Gan & Lee Pharmaceuticals, MannKind Corporation, Shanghai Fosun Pharmaceutical, Tonghua Dongbao Pharmaceutical, United Laboratories International, Julphar, Gland Pharma, and Wockhardt. Companies participating in the Global Insulin Market are implementing a range of strategic initiatives to strengthen their market position and maintain a competitive advantage. Major pharmaceutical firms are investing heavily in research and development to introduce advanced insulin formulations that offer improved efficacy, longer duration of action, and enhanced patient convenience. Strategic partnerships and licensing agreements with biotechnology firms are also helping companies accelerate innovation and expand product pipelines. Many manufacturers are focusing on the development of biosimilar insulin products to improve affordability and increase market penetration across emerging economies. In addition, firms are strengthening global distribution networks and expanding manufacturing capabilities to meet growing demand.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Type trends
  • 2.2.3 Product type trends
  • 2.2.4 Application trends
  • 2.2.5 Distribution channel trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of diabetes
    • 3.2.1.2 Advancements in insulin delivery systems
    • 3.2.1.3 Government initiatives and policies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of insulin
    • 3.2.2.2 Availability of alternative therapies
  • 3.2.3 Market opportunities
    • 3.2.3.1 Focus on pediatric diabetes
    • 3.2.3.2 Expansion of biosimilar insulin products
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by primary research)
  • 3.4.1 North America
    • 3.4.1.1 U.S.
    • 3.4.1.2 Canada
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Pricing analysis (Driven by primary research)
• 3.6 Pipeline analysis (Driven by primary research)
• 3.7 Diabetes landscape
  • 3.7.1 Number of diabetics worldwide, by region
  • 3.7.2 Countries with the highest number of diabetics worldwide in 2024
  • 3.7.3 Countries with the highest prevalence of diabetes worldwide in 2024
  • 3.7.4 Estimated number of diabetics worldwide in 2024 and a forecast for 2050
  • 3.7.5 Countries with the highest projected number of diabetics worldwide in 2050
  • 3.7.6 Top 10 countries based on diabetes health expenditure
  • 3.7.7 Global undiagnosed diabetes cases, by region
  • 3.7.8 Percentage of diabetics undiagnosed, by regions
• 3.8 Impact of AI and generative AI on the market
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
  • 4.2.3 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Human insulin
• 5.3 Insulin analog

Chapter 6 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Rapid-acting insulin
• 6.3 Long-acting insulin
• 6.4 Combination insulin
• 6.5 Biosimilar
• 6.6 Other products

Chapter 7 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Type 1 diabetes mellitus
• 7.3 Type 2 diabetes mellitus
• 7.4 Gestational diabetes

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Adocia
• 10.2 Biocon
• 10.3 Boehringer Ingelheim International
• 10.4 Eli Lilly and Company
• 10.5 Gan & Lee Pharmaceuticals
• 10.6 Gland Pharma
• 10.7 Julphar
• 10.8 MannKind Corporation
• 10.9 Novo Nordisk
• 10.10 Pfizer
• 10.11 Sanofi
• 10.12 Shanghai Fosun Pharmaceutical
• 10.13 Tonghua Dongbao Pharmaceutical
• 10.14 United Laboratories International
• 10.15 Wockhardt